NCT00154778已完成2 期
An Open,Multi-Center,Phase II Clinical Trial tO Evaluate Efficacy and Safety oF TAXOL(PACLITAXEL),UFT,and LEUCOVORIN in Patients With Advanced Gastric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- To evaluate the response rate
研究概览
简要总结
The purpose of this study is to evaluate the response rate of Paclitaxel combination chemotherapy with UFT and Leucovorin in patients with advanced gastric cancer.
详细描述
Since 1982,cancer has been the leading cause of death in Taiwan. In particular,gastric cancer is the fourth leading cause of death in male cancer patients and the sixth for female patients in 2000,accounting for an estimated 2,374 deaths. In recent years, the treatment of gastric cancer patients has gradually been improving due to advances in early diagnosis and surgical techniques. Although chemotherapy and radiation therapy have been used in either the adjuvant or palliative setting, their values are still limited due to their unacceptable toxicity or inadequate efficiency.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years old
- •Patients with histologically confirmed gastric adenocarcinoma, defined as locally advanced unresectable or metastatic or recurrent disease
- •Patients with at least one measurable lesion
- •ECOG performance status of 0,1 or 2
- •Patients with no prior chemotherapy and radiotherapy for metastatic disease (patients who have received and completed prior adjuvant chemotherapy at least 6 months prior to study enrollment may be enrolled into the study, prior taxane chemotherapy should be excluded)
- •Patients with physiological functions (bone marrow, heart, liver, kidney, etc.) meeting the following criteria: WBC >4000/mm3, ANC >1500/mm3, PLT >100,000/mm3, Hb >9.0g/dL, ALT<3 times the ULN (<5 times the ULN for liver metastasis cases), Total bilirubin <1.5mg/dL, Creatinine <the upper limit of normal
- •Accessible for treatment and follow-up
- •Give written informed consent
- •Women of child bearing potential must have a negative plasma or urine pregnancy test within 72 hours prior to start of the study medication
排除标准
- •Patients who received surgery within 14 days prior to enrollment
- •Patients with CNS metastasis
- •History of hypersensitivity related to the administration of polyoxyethylated-castor-oil (cremophor EL)-containing preparation (e.g. cyclosporin,etc.) or hardened-castor-oil-containing preparation (e.g. vitamin preparation for injection,etc.)
- •Patients with a history of severe hypersensitivity
- •Active infectious symptoms
- •Patients with active gastrointestinal bleeding, intestinal obstruction or other situation that dose not allow oral intake of medication
- •Patients with ascites that adversely affects performance status
- •Pre-existing CTC Grade 2 or greater neuropathy (motor or sensory)
- •Pregnant or nursing females
- •Patients who have participated in other clinical trials within 30 days prior to the first dose of the study drug
研究组 & 干预措施
A
Experimental
干预措施: Taxol, UFT,Leucovorin (Drug)
结局指标
主要结局
To evaluate the response rate
时间窗: 2003~2004
次要结局
- To determine time to progression and safety(2004~2005)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary SiteNeoplasm, Unknown PrimaryNCT00360360SCRI Development Innovations, LLC60
已完成
1 期
Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast CancerBreast NeoplasmNeoplasm MetastasisNCT00001507National Cancer Institute (NCI)107
已完成
2 期
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLCCarcinoma, Non-Small Cell Lung Cancer (NSCLC)NCT02392507Eli Lilly and Company54
已完成
2 期
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2Breast CancerNCT00003992National Cancer Institute (NCI)200
进行中（未招募）
2 期
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmNCT05554380National Cancer Institute (NCI)33